297 related articles for article (PubMed ID: 20489603)
1. Sugammadex: a selective relaxant-binding agent providing rapid reversal.
Rex C; Bergner UA; Pühringer FK
Curr Opin Anaesthesiol; 2010 Aug; 23(4):461-5. PubMed ID: 20489603
[TBL] [Abstract][Full Text] [Related]
2. Neuromuscular transmission: new concepts and agents.
de Boer HD
J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
[TBL] [Abstract][Full Text] [Related]
3. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
Ren WH; Jahr JS
Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
[TBL] [Abstract][Full Text] [Related]
4. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA
Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265
[TBL] [Abstract][Full Text] [Related]
5. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacology of sugammadex.
Bom A; Hope F; Rutherford S; Thomson K
J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
[TBL] [Abstract][Full Text] [Related]
7. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
[TBL] [Abstract][Full Text] [Related]
8. Sugammadex: another milestone in clinical neuromuscular pharmacology.
Naguib M
Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
[TBL] [Abstract][Full Text] [Related]
9. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
[TBL] [Abstract][Full Text] [Related]
10. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
[TBL] [Abstract][Full Text] [Related]
11. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.
Plaud B; Meretoja O; Hofmockel R; Raft J; Stoddart PA; van Kuijk JH; Hermens Y; Mirakhur RK
Anesthesiology; 2009 Feb; 110(2):284-94. PubMed ID: 19194156
[TBL] [Abstract][Full Text] [Related]
12. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
Sacan O; White PF; Tufanogullari B; Klein K
Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
[TBL] [Abstract][Full Text] [Related]
13. Sugammadex: a novel agent for the reversal of neuromuscular blockade.
Nicholson WT; Sprung J; Jankowski CJ
Pharmacotherapy; 2007 Aug; 27(8):1181-8. PubMed ID: 17655516
[TBL] [Abstract][Full Text] [Related]
14. Sugammadex: the first selective binding reversal agent for neuromuscular block.
Kovac AL
J Clin Anesth; 2009 Sep; 21(6):444-53. PubMed ID: 19833281
[TBL] [Abstract][Full Text] [Related]
15. The concept behind sugammadex.
Epemolu O; Bom A
Rev Esp Anestesiol Reanim; 2014 May; 61(5):272-6. PubMed ID: 24636599
[TBL] [Abstract][Full Text] [Related]
16. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.
White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME
Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792
[TBL] [Abstract][Full Text] [Related]
17. An update on sugammadex sodium.
Welliver M; Cheek D
AANA J; 2009 Jun; 77(3):219-28. PubMed ID: 19645172
[TBL] [Abstract][Full Text] [Related]
18. A novel approach to reversal of neuromuscular blockade.
Della Rocca G; Pompei L
Minerva Anestesiol; 2009 May; 75(5):349-51. PubMed ID: 19412157
[TBL] [Abstract][Full Text] [Related]
19. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
de Boer HD; van Esmond J; Booij LH; Driessen JJ
Paediatr Anaesth; 2009 Dec; 19(12):1226-8. PubMed ID: 19863737
[TBL] [Abstract][Full Text] [Related]
20. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
Suy K; Morias K; Cammu G; Hans P; van Duijnhoven WG; Heeringa M; Demeyer I
Anesthesiology; 2007 Feb; 106(2):283-8. PubMed ID: 17264722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
